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Cost-effective therapy remission assessment in
lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-
D-glucose–positron emission tomography/computed
tomography: is an end of treatment exam necessary
in all patients?
K. Strobel1*, N. G. Schaefer2, C. Renner2, P. Veit-Haibach1, D. Husarik1, A. Y. Koma1 &
T. F. Hany1
1Department of Nuclear Medicine, University Hospital Zurich; 2Department of Internal Medicine, Oncology, University Hospital Zurich, Zurich, Switzerland
Background: The aim of this study was to evaluate the necessity of 2-[fluorine-18]fluoro-2-deoxy-D-glucose–
positron emission tomography/computed tomography (FDG–PET/CT) after end of treatment in lymphoma patients
who had an interim FDG–PET/CT.
Patients and methods: In 38 patients with Hodgkin’s disease (HD) and 30 patients with non-Hodgkin’s lymphoma
(NHL) interim PET/CT (intPET) after two to four cycles of chemotherapy and PET/CT after completion of first-line
treatment (endPET) were carried out. Cost reduction was retrospectively calculated for the potentially superfluous
endPET examinations.
Results: In 31 (82%) HD patients, intPET demonstrated complete remission (CR) which was still present on endPET.
The remaining seven HD patients (18%) had partial remission (PR) on intPET. For NHL, 22 (73%) patients had CR on
intPET analysis which was still present on endPET. In the remaining eight NHL patients, intPET revealed PR in seven
and stable disease in one patient. None of all intPET complete responders progressed until the end of therapy. Thus,
of the 196 PET/CT’s carried out in our study population, 53 endPET’s (27.0%) were carried out in interim complete
responders.
Conclusion: End-treatment PET/CT is unnecessary if intPET shows CR and the clinical course is uncomplicated.
An imaging cost reduction of 27% in our study population could have been achieved by omitting end of treatment
FDG–PET/CT in interim complete responders.
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introduction
Lymphomas are very sensitive to chemotherapy and radiotherapy.
Recent developments in treatment have improved the outcome
markedly and are cost-effective [1, 2]. Most patients with
Hodgkin’s disease (HD) or non-Hodgkin’s lymphoma (NHL) can
be treated successfully with curative intent. Because of its superior
diagnostic performance 2-[fluorine-18]fluoro-2-deoxy-D-
glucose–positron emission tomography/computed tomography
(FDG–PET/CT) has replaced CT alone in many institutions for
primary staging in patients with newly diagnosed lymphoma [3–6].
In several studies, FDG–PET has also proven to be the best
noninvasive imaging tool for early remission assessment [7]. The
use of PET/CT in staging and therapy remission assessment in
lymphoma patients are under discussion and the published
recommendations are controversial [8–10]. PET/CT is a relatively
expensive imaging technique with mean costs per scan of 1900
US dollars [11]. Furthermore, the effective radiation dose of
a single whole body PET/CT scan can reach up to 25 mSv—another
argument to avoid unnecessary PET/CT examinations,
especially in young patients [12]. Only a few studies deal with
the topic of cost-effective use of PET/CT in oncology [13–15].
The purpose of this retrospective study was to evaluate the
clinical value and necessity of FDG–PET/CT after the end of
first-line therapy in patients with HD and NHL compared with
results of interim staging FDG–PET/CT after two to four cycles
of chemotherapy. The second aim of the study was to calculate
the potential cost reduction by omitting the end of treatment
PET/CT examinations in complete interim responders.
patients and methods
patients
We received approval from our institutional review board to undertake
this study.
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All PET/CT investigations carried out from January 2001 to August 2005
in our institution for staging and therapy assessment in lymphoma patients
were reviewed retrospectively. Inclusion criteria for this study were: (i)
a histologically proven HD or NHL [large B-cell lymphoma (DLBCL),
burkitt-like lymphoma or Burkitt’s lymphoma], (ii) an interim PET/CT
(intPET) after two to four cycles of chemotherapy and (iii) an end of
treatment PET/CT, carried out 6 weeks after chemo-/chemoimmunotherapy
or 10 weeks after radiotherapy. This resulted in a study population of 68
patients; 38 patients with HD [27 male, 11 female; mean age 34.2 years,
range 10–71 years, 24 (63.2%) stage I/II and 14 (36.8%) stage III/IV]. Of
these HD patients, 25 had nodular sclerosis, five had mixed cellularity and
eight had lymphocyte-rich classical type. Thirty patients with NHL (20 male,
10 female; mean age 46.3 years, range 17–74 years), comprised of 15 (50%)
stage I/II and 15 (50%) stage III/IV. Twenty-six patients had a DLBCL,
two patients a burkitt-like lymphoma, one a Burkitt’s lymphoma and one
a post-transplantation lymphoproliferative B-cell NHL lymphoma (PTLD).
Patient characteristics are summarized in Table 1.
treatment
Patients were treated according to departmental protocols. Twelve of the 38
Hodgkin’s patients were treated with four to eight cycles of bleomycin,
etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine and
prednisone, 26 with four to eight cycles of ABVD (adriamycin, bleomycin,
vinblastin and dacarbazine). Thirteen HD patients received additional
radiotherapy.
Twenty-three of the 26 patients with DLBCL were treated with four to six
cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine
and prednisone). One patient with DLBCL was treated with six cycles
CHOP. Three patients (one DLBCL, one Burkitt’s lymphoma, one burkitt-
like B-cell lymphoma) were treated with rituximab, hyperfractionated
cyclophosphamide, vincristine, doxorubicin and dexamethason. Two
patients (one DLBCL, one PTLD) were treated with four cycles rituximab
and one patient with burkitt-like lymphoma was treated with two cycles
R-CHOP and four cycles of etoposide, prednisone, vincristine,
cyclophosphamide and doxorubicin. Seven of the 30 NHL patients received
additionally radiotherapy.
PET/CT imaging
All data were acquired on a combined PET/CT in-line system (Discovery LS
or Discovery ST, GE Health Systems, Milwaukee, WI). This system
integrates a PET scanner (GE Advance Nxi, GE Health Systems, Milwaukee,
WI) with a multislice helical CT (LightSpeed plus or Lightspeed 16; GE
Health Systems, Milwaukee, WI) and permits the acquisition of coregistered
CT and PET images in one session.
Patients fasted for at least 4 h before scanning, which started 60 min after
the injection of 350–400 MBq of 18F-FDG. Oral CT contrast agent
(Micropaque Scanner, Guerbet AG, Aulnay-sous-bois, France) was
administered 15 min before the injection of 18F-FDG. Patients were
examined in the supine position. No intravenous contrast agent was given.
Initially, the CT scan was acquired starting from the level of the head using
the following parameters: 40 mAs, 140 kV, 0.5 sec/tube rotation, slice
thickness 4.25 mm, scan length 867 mm, data-acquisition time 22.5 s. The
CT scan was acquired during breath holding in the normal expiratory
position. For patients with lymphoma manifestations in the lower
extremities, scanning of the lower legs was added.
Immediately following the CT acquisition, a PET emission scan was
carried out with an acquisition time of 3 min per cradle position with
a one-slice overlap. The eight to nine cradle positions from the knees to the
head resulted in an acquisition time of 24–27 min. The CT data were used
for the attenuation correction and images were reconstructed using
a standard iterative algorithm (OSEM). All images acquired were viewed
with a software providing multiplanar reformatted images of PET alone, CT
alone and fused PET/CT with linked cursors using a commercially available
sorkstation (Xeleris, GE Health Systems, Milwaukee, WI).
SUV max measurement
Semiquantitative analysis of FDG uptake in the lymphoma deposits was
carried out by measuring the standard uptake value (SUV) max. A personal
scale (Tanita, model 2001; Tanita, Tokyo, Japan) with an integrated foot-to-
foot bioelectric impedance analyzer was used to determine the lean body
mass (LBM) of the patients. The manufacture-supplied equations for this
model incorporate sex, mass, height and a measured impedance value to
determine the percentage of body fat and for calculation of LBM. By using
attenuation-corrected PET data, SUV max. were calculated with the
following equation by creating a freehand region of interest over the
complete visible lesion on the fused PET/CT image: SUV max(lbm) =
(LBMCFDG)/dose where LBM is measured in grams, CFDG is the
concentration of 18F-FDG in Becquerel’s per milliliter, and dose is the
injected dose measured in Becquerel’s.
PET/CT interpretation
The PET/CT investigations were reviewed by two experienced readers (one
reader double board certified in radiology and nuclear medicine and the
other reader board certified in radiology and with 2 years experience in PET/
CT reading) by consensus. All PET/CT examinations were evaluated
regarding the presence and extent of FDG-positive lymphoma and FDG-
negative structural residual soft-tissue abnormalities during/after therapy.
Therapy remission was assessed using the following criteria: complete
remission, FDG uptake resolved completely; partial remission, >25%
decrease of SUV max; stable disease, <25% increase or <15% decrease of
SUV max; progressive disease (PD), >25% increase of SUV max, new FDG-
positive manifestations [16]. In accordance with the recommendations of
the International Harmonization Project (IHP) for PET use in patients with
lymphoma mediastinal blood pool structures (MBPS) uptake being used as
a ‘reference background tissue’ to define PET positivity for a residual mass
(RM) ‡2 cm in greatest transverse diameter [9]. RM was only considered
positive when uptake intensity was greater than MBPS. RM’s <2 cm were
considered positive if the uptake was greater than their background activity.
FDG–PET/CT costs
Costs for a partial body FDG–PET/CT investigation with our standard low-
dose CT protocol which is used in our institution for staging and therapy
assessment of lymphoma patients, were calculated at 1900 US dollars.
Table 1. Patients’ characteristics
Characteristic HD NHL
N 38 30
M : F 27 : 11 20 : 10
Mean age 34.2 46.3
Age range 10–71 17–74
Histology/type Nodular sclerosis: 25,
Mixed cellularity: 5,
Lymphocytic-rich classic: 8
DLBCL: 26,
Burkitt-like: 2,
Burkitt: 1, PTLD: 1
Stage I/II 24 15
Stage III/IV 14 15
HD, Hodgkin’s disease; NHL, non-Hodgkin lymphoma; M, male;
F, female; DLBCL, diffuse large B-cell lymphoma; PTLD, post-
transplantation lymphoproliferative B-cell NHL lymphoma.
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This figure approximates the actual costs of a PET/CT scan in the United
States [11].
results
HD patients
All 37 baseline PET/CTs (100%) in the HD patients were FDG
positive (mean SUV max 10.6, range 4.0–29.9). In 31 of 38 HD
patients (82%) intPET showed CR. PET/CT after completion of
first-line treatment (endPET) confirmed CR in all of these
patients (Fig. 4). In seven HD patients (18%) intPET showed PR
(mean SUV max 4.3, range 1.8–6.8) followed by CR in three, PR
in three (mean SUV max 2.5, range 1.9–2.5) and PD (SUV max
8.9) in one patient. Results of the HD group are summarized in
Figure 1.
NHL patients
All 23 baseline PET/CTs in the NHL patients were FDG positive
(mean SUV max 16.5, range 5.4–40.0). In 22 of 30 NHL patients
(73%) intPET showed CR and endPET was negative in all of
these patients. None of these patient progressed until the end of
therapy. In the remaining eight NHL patients seven (20%)
showed PR on intPET (mean SUV max 3.6, range 2.6–6.5)
followed by CR in five, by PR in one (SUV max 3.2) and PD
(SUV max 12.7) in another patient. One patient had stable
disease at intPET (SUV max 6.1) and CR at endPET. Results of
the NHL group are summarized in Figure 2.
Eleven of 68 patients who were in CR on intPET still had
remaining soft-tissue abnormalities on the corresponding CT.
In three patients therapy was changed because of the findings
in the intPET; one patient with a vaginal B lymphoma showed
stable disease on inPET after four cycles of chemotherapy so that
the chemotherapy was stopped and radiotherapy was carried
out. The PET/CT scan after the end of radiotherapy showed
a complete remission (CR). In one patient with DLBCL of the
mediastinum intPET showed partial remission (PR) after four
cycles of R-CHOP and chemotherapy was stopped and radiation
therapy was carried out showing CR at the end of treatment. The
last of the three patients with mediastinal Hodgkin’s lymphoma
showed CR after two cycles of ABVD so that six cycles were
completed but additionally planned radiotherapy was omitted
because of the inPET findings. PET/CT after end of treatments
showed again CR.
cost calculation
One hundred and ninety-six PET/CT’s were carried out in our
study population. Fifty-three endPET’s were carried out in
complete interim responders. Overall costs for 196 18F-FDG–
PET/CT scans (60 basPET’s, 68 intPET’s, 68 endPET’s) in our
population were calculated with 372 400 US dollars. In our
study population, an overall diagnostic imaging cost reduction
of 27.0% or 102 600 US dollars could have been achieved by
omitting 53 end of treatment FDG–PET/CT’s in the interim
complete responders.
discussion
In contradiction to the current recommendations [8, 10], our
results indicate that PET/CT after end of treatment is
unnecessary in HD and DLBCL patients if intPET shows
a complete remission and the clinical course is uncomplicated.
In our study population, an overall diagnostic imaging cost
reduction of 27% could have been achieved by omitting
end of treatment FDG-PET/CT in interim complete
responders.
Because many lymphoma types are reliably FDG positive,
some authors recommend a baseline PET/CT only for
lymphoma types where the FDG avidity is less predictable such
as marginal-zone lymphoma, mantle cell lymphoma or follicular
lymphoma [17]. Several studies confirmed that PET/CT is
superior to other imaging methods such as CT or Gallium
scintigraphy in the staging situation and provides a more
accurate assessment of the stage of the disease [18–20]. Partridge
et al. [21] reported a stage and therapy change of 25% in
Hodgkin’s patients with baseline PET compared with baseline
CT. A disadvantage of a missing baseline investigation is that the
interpretation of an interim scan can be very difficult and the
categorization into progressive, stable disease or PR according
to the established criteria may be even impossible if the baseline
SUV max of the lesions is not available.
The assessment of therapy remission is one of the most
challenging aspects in lymphoma patients. Morphological
imaging modalities such as CT and magnetic resonance imaging
Figure 1. Results of therapy assessment with (PET/CT) in 38 HD patients. Positron emission tomography/computed tomography.
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fail to predict the clinical outcome after therapy in lymphoma
patients [22, 23]. 18F-FDG–PET/CT has been established
quickly after introducing into clinical practice in staging and
therapy monitoring in lymphoma patients [5–7]. The main goal
of first-line treatment in lymphoma patients is to obtain a
CR, because a CR is associated with a better clinical outcome
[1]. A negative FDG–PET alone after first-line treatment is
associated with a better progression-free survival (PFS) and
overall survival. Jerusalem et al. [24] evaluated a mixed
population of 54 HD and DLBCL patients and found a 1-year
PFS of 0% for patients with a PET-positive lesion versus 86% for
patients with CR at the end of therapy. Thirty-one (82%) of 38
HD patients in our study showed CR in intPET and all remained
FDG negative in end-treatment PET/CT. In our NHL group, 22
of 30 patients (73.3%) had CR at intPET and all of them also
had a negative end-treatment PET/CT. In other words, at the
end of first-line treatment we had no progress in all interim
complete responders. Our results are supported by findings of
other studies. Hutchings et al. investigated 85 patients with HD
after two or three cycles of chemotherapy. In 63 patients intPET
was negative. In 27 of these 63 patients an endPET was carried
out which was negative in 25 patients and positive at site of
previous disease in two patients. None of the 27 intPET-negative
patients relapsed (median follow-up 3.3 years), although two
endPET’s were positive [25]. Hutchings et al. also investigated
121 DLBCL patients. In 50 patients intPET was negative. In 19
of these patients an endPET was carried out, which was negative
in every case. Interestingly, in the 31 patients without endPET
there was a higher rate of progression (four patients = 13%)
than in the intPET-negative and endPET-negative patients (one
patient = 5%) [26]. Haioun et al. [27] investigated 90 patients
with aggressive lymphoma and reported that none of the 54
‘early-PET’ negative patients became positive after four cycles.
Spaepen et al. investigated 70 patients with aggressive DLBCL.
They had 37 patients with a negative midtreatment PET
reported. All of these patients had negative PET’s after
completion of first-line therapy. Thirty-one of these patients
had a durable complete remission and, five patients relapsed
after a median of 365 days. One patient had a negative PET after
end of treatment but never achieved a CR because of persistence
lymphoma in the bone marrow [28]. Kostakoglu et al. [29]
reported that an interim FDG–PET after one cycle of
chemotherapy correlates better with the outcome than scans
after completion of chemotherapy. These data indicate that the
interim FDG–PET scan provides more prognostic information
than the FDG–PET after end of treatment. Results from
outcome studies, where therapy is changed in patients with
PET-positive interim scans, are still not available. Thus, the IHP
group recommends that intPET should only be done in clinical
trials. We observed in our study population that PET/CT
findings of intPET changed therapy in three patients; in two
patients additional radiotherapy was carried out because of
persistent FDG-uptake in intPET and in one patient
radiotherapy was omitted because of complete remission in
intPET. Since this study was conducted retrospectively, no
definitive conclusions can be drawn regarding the influence of
PET/CT on therapy management in these patients. According to
other authors, we believe that PET/CT clearly has the potential
to influence the lymphoma therapy [30].
From this data the question arises, whether it is necessary to
carry out an end of treatment scan in interim complete
responders or if these costs can be spared. From a psychological
point of view, it might be understandable that the patient
and treating oncologist want to document the successful
treatment at the end of the therapy with imaging but in our
opinion, this argument is not strong enough to justify
a costly investigation with additional radiation exposure in
patients already at risk for second tumors. It has also to be
taken into account that every PET/CT imaging has the
risk of producing misleading PET-positive findings such as
thymus rebound, infections or uptake in brown fat all
of which can be misinterpreted as a disease recurrence
[31–33].
Figure 2. Results of therapy assessment with positron emission tomography/computed tomography (PET/CT) in 30 NHL patients. Positron emission
tomography/computed tomography; SD, stable disease; PR, partial remission; CR, complete remission; PD, progressive disease.
Figure 3. Proposed simplified algorithm for effective use of 2-[fluorine-
18]fluoro-2-deoxy-D-glucose–positron emission tomography/computed
tomography (FDG–PET/CT) in therapy assessment of lymphoma patients.
CR, complete remission.
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Figure 4. A 17-year-old patient with histologically proven Hodgkin’s disease (HD). Coronal maximum intensity projection (MIP) image (a) of the baseline
positron emission tomography/computed tomography (PET/CT) before therapy showing supradiaphragmatic (upper arrow) and infradiaphragmatic (lower
arrow) lymph node involvement. Additionally, multifocal bone involvement (arrowheads) is observed. Axia-fused PET/CT image (b) showing one focal
FDG-active osteolytic lesion in the left ischiac bone (arrow). Stage IV lymphoma was diagnosed. Interim PET/CT after three cycles of chemotherapy [adriamycin,
bleomycin, vinblastin and dacarbazine (ABVD)] showing complete disappearance of pathologic FDG uptake but increased uptake in the brown fatty tissue in the
cervical, supraclavicular (c, MIP image, upper arrow), mediastinal and abdominal region (lower arrow). Axial PET/CT image (d) demonstrating that the FDG
uptake is localized in the supraclavicular brown fatty tissue (arrows) and not in cervical lymph nodes. The bone lesion (e, arrow) shows no FDG uptake anymore.
Complete remission was diagnosed. PET/CT after end of treatment (eight cycles ABVD) showing disappearance of all pathologic FDG uptakes (f, g arrow) as well as
complete restitution of FDG uptake in the brown fatty tissue consistent with persistent complete remission.
original article Annals of Oncology
662 | Strobel et al. Volume 18 | No. 4 | April 2007
Our finding, therefore, do not support the work by
Spaepen et al. [8] who proposed an algorithm for the
implementation of FDG–PET in the management of lymphoma
patients where they recommended an endPET in patients
with negative intPET. Spaepen et al. even recommended follow-
up scans in complete responders with DLBCL independent of
the initial stage and in HD patients stage III and IV. In patients
with HD stage I/II and CR they recommended no follow-up
scans. Recently published recommendations of the IHP group
state, ‘‘PET should be routinely used for remission assessment
at the conclusion of therapy in patients with HD and DLBCL’’
[9]. There might still be the rare situation of a very early progress
between inPET and endPET in complete interim responders
although neither in our study population nor in one of the
studies mentioned above such a case was described. In our
experience these patients develop clinical symptoms such as
night sweats, palpable masses or increasing lactate
dehydrogenase, and thus restaging with PET/CT in this
situation is strongly recommended.
We have summarized our approach cost-effective use of
FDG–PET/CT in patients with HD and NHL in a simplified
algorithm (Figure 3).
In conclusion, our data indicates that PET/CT after end of
treatment is superfluous if intPET shows CR. Therefore,
a substantial cost reduction might be achieved by omitting end
of treatment FDG–PET/CT in interim complete responders.
acknowledgement
The authors thank our guest Victor Kalff for his help to prepare
the manuscript.
references
1. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared
with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl
J Med 2002; 346: 235–242.
2. Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera) for aggressive non-
Hodgkin’s lymphoma: systematic review and economic evaluation. Health
Technol Assess 2004; 8:iii, ix–xi, 1–82.
3. Schaefer NG, Hany TF, Taverna C et al. Non-Hodgkin lymphoma and
Hodgkin disease: coregistered FDG PET and CT at staging and restaging—do
we need contrast-enhanced CT? Radiology 2004; 232: 823–s829.
4. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET
with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994;
190: 111–116.
5. Hicks RJ, Mac Manus MP, Seymour JF. Initial staging of lymphoma with positron
emission tomography and computed tomography. Semin Nucl Med 2005; 35:
165–175.
6. Raanani P, Shasha Y, Perry C et al. Is CT scan still necessary for staging in
Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol
2006; 17: 117–122.
7. Jerusalem G, Hustinx R, Beguin Y, Fillet G. Evaluation of therapy for lymphoma.
Semin Nucl Med 2005; 35: 186–196.
8. Spaepen K, Stroobants S, Verhoef G, Mortelmans L. Positron
emission tomography with [(18)F]FDG for therapy remission monitoring
in lymphoma patients. Eur J Nucl Med Mol Imaging 2003; 30 (Suppl 1):
S97–105.
9. Juweid ME, Stroobants S, Hoekstra OS et al. Use of Positron Emission
Tomography for Response Assesment of Lymphoma: Consensus of the Imaging
Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol
2007.
10. Juweid ME, Wiseman GA, Vose JM et al. Response assessment of aggressive
non-Hodgkin’s lymphoma by integrated International Workshop Criteria and
fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol
2005; 23: 4652–4661.
11. Berger M, Gould MK, Barnett PG. The cost of positron emission tomography in
six United States Veterans Affairs hospitals and two academic medical centers.
Am J Roentgenol 2003; 181: 359–365.
12. Brix G, Lechel U, Glatting G et al. Radiation exposure of patients undergoing
whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med 2005;
46: 608–613.
13. Heinrich S, Goerres GW, Schafer M et al. Positron emission tomography/
computed tomography influences on the management of resectable
pancreatic cancer and its cost-effectiveness. Ann Surg 2005; 242:
235–243.
14. Valk PE, Abella-Columna E, Haseman MK et al. Whole-body PET imaging with
[18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch
Surg 1999; 134:503–511; Discussion 511-503.
15. Klose T, Leidl R, Buchmann I, Brambs HJ, Reske SN. Primary staging of
lymphomas: cost-effectiveness of FDG-PET versus computed tomography. Eur
J Nucl Med 2000; 27: 1457–1464.
16. Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical
tumour remission using [18F]-fluorodeoxyglucose and positron emission
tomography: review and 1999 EORTC recommendations. European Organization
for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer
1999; 35: 1773–1782.
17. Guermazi A, Juweid ME. Commentary: PET poised to alter the current paradigm
for remission assessment of non-Hodgkin’s lymphoma. Br J Radiol 2006; 79:
365–367.
18. la Fougere C, Hundt W, Brockel N et al. Value of PET/CT versus PET and CT
performed as separate investigations in patients with Hodgkin’s disease and
non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 2006.
19. Kostakoglu L, Leonard JP, Kuji I et al. Comparison of fluorine-18
fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in
evaluation of lymphoma. Cancer 2002; 94: 879–888.
20. Schaefer NG, Strobel K, Taverna C, Hany TF. Bone involvement in
patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol
Imaging 2006.
21. Partridge S, Timothy A, O’Doherty MJ et al. 2-Fluorine-18-fluoro-2-deoxy-D
glucose positron emission tomography in the pretreatment staging of Hodgkin’s
disease: influence on patient management in a single institution. Ann Oncol
2000; 11: 1273–1279.
22. Hill M, Cunningham D, MacVicar D et al. Role of magnetic resonance imaging in
predicting relapse in residual masses after treatment of lymphoma. J Clin
Oncol 1993; 11: 2273–2278.
23. Mikhaeel NG, Timothy AR, O’Doherty MJ et al. 18-FDG-PET as a prognostic
indicator in the treatment of aggressive Non-Hodgkin’s Lymphoma-comparison
with CT. Leuk Lymphoma 2000; 39: 543–553.
24. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission
tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in
Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and
prognostic value than classical computed tomography scan imaging. Blood
1999; 94: 429–433.
25. Hutchings M, Mikhaeel NG, Fields PA et al. Prognostic value of interim FDG-PET
after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol
2005; 16: 1160–1168.
26. Mikhaeel NG, Hutchings M, Fields PA et al. FDG-PET after two to three cycles of
chemotherapy predicts progression-free and overall survival in high-grade
non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514–1523.
27. Haioun C, Itti E, Rahmouni A et al. [18F]fluoro-2-deoxy-D-glucose
positron emission tomography (FDG-PET) in aggressive lymphoma: an
early prognostic tool for predicting patient outcome. Blood 2005; 106:
1376–1381.
Annals of Oncology original article
Volume 18 | No. 4 | April 2007 doi:10.1093/annonc/mdl493 | 663
28. Spaepen K, Stroobants S, Dupont P et al. Early restaging positron
emission tomography with (18)F-fluorodeoxyglucose predicts outcome in
patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 2002; 13:
1356–1363.
29. Kostakoglu L, Coleman M, Leonard JP et al. PET predicts prognosis after 1 cycle
of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med
2002; 43: 1018–1027.
30. Juweid ME, Cheson BD. Positron-emission tomography and assessment of
cancer therapy. N Engl J Med 2006; 354: 496–507.
31. Brink I, Reinhardt MJ, Hoegerle S et al. Increased activity in the thymus gland
studied with 18F-FDG PET: age dependency and frequency after chemotherapy.
J Nucl Med 2001; 42: 591–595.
32. Castellucci P, Nanni C, Farsad M, et al. Potential pitfalls of 18F-FDG PET in
a large series of patients treated for malignant lymphoma: prevalence and scan
interpretation. Nucl Med Commun 2005; 26: 689–694.
33. Sandherr M, von Schilling C, Link T et al. Pitfalls in imaging Hodgkin’s disease
with computed tomography and positron emission tomography using fluorine-18-
fluorodeoxyglucose. Ann Oncol 2001; 12: 719–722.
original article Annals of Oncology
664 | Strobel et al. Volume 18 | No. 4 | April 2007
